Real-world effectiveness and safety of adjuvant capecitabine in triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy.
Anbarasan Sekar, Sanjana Malokar, Sushmita Rath, Prabhat Bhargava et autres
543 Background: The presence of residual disease in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy is associated with high recurrence risk and poor prognosis. The CREAT-X study demonstrated improved recurrence risk and survival outcomes with adjuvant capecitabine in this population [1]. We …
in (code pays fourni par la source)
0 citations
Journal of Clinical Oncology